Associate Professor of Nephrology @inselgruppe and @unibern. Kidney stone and rare kidney disease enthusiast. Passion for skiing, climbing and alpinism.
- Tweets 131
- Following 109
- Followers 78
- Likes 115
ALT Panel A: Time to first British Isles Lupus Assessment Group (BILAG)–defined flare. The time to event in weeks was calculated as the event date minus the randomization date plus 1, divided by 7. Panel B: Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) scores in the two trial groups at all assessed time points; only observed values are shown, and the I bars indicate Wald 95% confidence intervals.
ALT Panels A and B: The percentage of patients with normal C3 complement levels (≥0.9 g per liter) and normal C4 complement levels (≥0.1 g per liter), respectively, per visit, from baseline through week 52, among patients with abnormal baseline levels (for C3 levels, 87 patients in the obinutuzumab group and 85 patients in the placebo group; for C4 levels, 67 patients in the obinutuzumab group and 80 patients in the placebo group). Panel C: The percentage of patients with normal anti–double-stranded DNA antibody levels (<100 IU per milliliter) per visit, from baseline through week 52, among patients with abnormal baseline levels (86 patients in the obinutuzumab group and 81 patients in the placebo group). Panel D: The percentage of patients with B-cell depletion per visit, from baseline through week 52, in the obinutuzumab and placebo groups.
